Gossamer Bio, Inc.
GOSSDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How GOSS's past catalysts played out
GB001
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
GB002 (seralutinib)
Pulmonary Artery Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB001 | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | - | - |
GB002 (seralutinib) | Phase 2 | Pulmonary Artery Hypertension | - | - |
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
1 drug in this indication
Pulmonary Artery Hypertension
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Gossamer Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Gossamer Bio, Inc.'s (GOSS) pipeline across Phase 2. Its lead program is GB001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Gossamer Bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Gossamer Bio, Inc. (GOSS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GOSS biotech catalysts?→
Add GOSS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Gossamer Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.